Cancer stem cell growth inhibitor using miRNA
AssigneeCancerStem Tech Inc.
InventorsXin Wu, Masaki Mori, Hirofumi Yamamoto
Life of this patent
Estimating the term…
Abstract
The purpose of the present invention is to provide a nucleic acid medication for cancer treatment, the medication being capable of suppressing the growth of cancer stem cells and thus effectively treating cancer. hsa-miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g, hsa-miR-181a-5p, hsa-miR-362-5p, and hsa-miR-608 have remarkably excellent growth inhibitory action on cancer stem cells and are thus useful as a nucleic acid medication for the treatment of various cancers.
Claims5
A method of inhibiting proliferation of a cancer stem cell, the method comprising administering to the cancer stem cell:
- (a) at least one miRNA as an active ingredient, wherein the at least one miRNA is:
- (1) hsa miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g and/or hsa-miR-181a-5p delivered to pancreatic tumor cells;
- (2) hsa-miR-136-5p, hsa-miR-3065-3p, and/or hsa-miR-181a-5p delivered to gastric tumor cells;
- (3) hsa-miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g, hsa-miR-181a-5p, hsa-miR-362-5p, and/or hsa-miR-608 delivered to human large bowel cancer cells;
- or
- (4) hsa-miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g, and/or hsa-miR-181a-5p delivered to esophageal cancer cells;
- and
- (b) an miRNA transfer agent;
- wherein the at least one miRNA and the miRNA transfer agent are administered simultaneously with an anticancer drug, or before and/or after administration of an anticancer drug.
A method for treating cancer, comprising a step of administering to a cancer patient a therapeutically effective amount of:
- (a) at least one miRNA, wherein the at least one miRNA is:
- (1) hsa miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g and/or hsa-miR-18 la-5p delivered to pancreatic tumor cells;
- (2) hsa-miR-136-5p, hsa-miR-3065-3p, and/or hsa-miR-181a-5p delivered to gastric tumor cells;
- (3) hsa-miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g, hsa-miR-181a-5p, hsa-miR-362-5p, and/or hsa-miR-608 delivered to human large bowel cancer cells;
- or
- (4) hsa-miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g, and/or hsa-miR-181a-5p delivered to esophageal cancer cells;
- and
- (b) an miRNA transfer agent.
Dependencies are inferred from the claim text.